Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma Inc. (BNTC)
US:NASDAQ Investor Relations:
benitec.com/for-investors/investor-faqs
Company Research
Source: GlobeNewswire
-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and interim clinical study results for the first Cohort 2 Patient will be reported in a late-breaking poster presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference on March 9, 2026- HAYWARD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced the acceptance of a late-breaking abstract for the BB-301 Phase 1b/2a Clinical Treatment Study ongoing in Oculopharyngeal Muscular Dystrophy Patients (OPMD) with moderate dysphagia. Interim clinical study results for Patients enrolled int
Show less
Read more
Impact Snapshot
Event Time:
BNTC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTC alerts
High impacting Benitec Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
BNTC
News
- Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational UpdateGlobeNewswire
- Benitec Biopharma: BB-301's Early OPMD Data And Cash Infusion Justify A Bullish Upgrade [Seeking Alpha]Seeking Alpha
- Benitec Biopharma (NASDAQ:BNTC) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response [Yahoo! Finance]Yahoo! Finance
- Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of ResponseGlobeNewswire
BNTC
Earnings
- 2/12/26 - Miss
BNTC
Sec Filings
- 2/12/26 - Form 8-K
- 2/12/26 - Form 10-Q
- 2/11/26 - Form EFFECT
- BNTC's page on the SEC website